The overall objective of this Program Project Grant is to itdentify and test new ways to prevent, detect, and treat colon cancer through an increased understanding ofthe genetics, cell biology and pathogenesis of this malignancy and its precursor lesion, the adenomatous polyp. Our Program focuses on the definition of the molecular mechanisms that underlie the development ofcolon cancer following mutations in the tumor suppressor adenomatous polyposis coll (APC). Since APC is mutated in up to 85% of colorectal cancers and adenomatous polyps, improved understanding of the molecular alterations that characterize tumors harboring APC mutations could result in the identification of novel strategies for improved diagnosis and treatment of colorectal polyps and cancer. The goals of the present Program are centered on APC and other proteins that help mediate its oncogenic effects. These goals are tested in hypotheses using a variety of experimental approaches that include: 1. Utilizing high-risk, inherited APC gene mutation carriers and families in a novel interventional clinical trial that will test combined inhibition of cyclooxygenases and EGFR, two proteins that we found in the previous funding cycle to mediate the oncogenic effects of mutant APC. 2. Characterizing altered mechanisms associated with the loss of APC function, with a focus on events related to decreased retinoic acid production, excess signaling through EGFR, LEF1, TCF4 and deregulated Wnt signaling. 3. Assessing the role of KRAS as a permissive factor in colon cancer development following APC mutation. 4. Evaluating novel pathways for activation of EGFR mediated by inflammatory lipid mediators, including studies in genetically-altered mice and pre-clinical trials in murine models of colon cancer. These investigations, based on work from the previous cycle, involve carcinogenic cell functions of proliferation, differentiation, apoptosis and inflammation and, as noted, will be tested in a systems biology and translational construct utilizing cell culture, zebrafish, mouse and human models.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA073992-13
Application #
8234106
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (O1))
Program Officer
Malone, Winfred F
Project Start
1998-08-10
Project End
2015-02-28
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
13
Fiscal Year
2012
Total Cost
$2,182,390
Indirect Cost
$720,205
Name
University of Utah
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Delker, Don A; Wood, Austin C; Snow, Angela K et al. (2018) Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia. Cancer Prev Res (Phila) 11:4-15
Sample, Danielle C; Samadder, N Jewel; Pappas, Lisa M et al. (2018) Variables affecting penetrance of gastric and duodenal phenotype in familial adenomatous polyposis patients. BMC Gastroenterol 18:115
Fuller, Andrew K; Bice, Benjamin D; Venancio, Ashlee R et al. (2018) A Method to Define the Effects of Environmental Enrichment on Colon Microbiome Biodiversity in a Mouse Colon Tumor Model. J Vis Exp :
Bice, Benjamin D; Stephens, Megan R; Georges, Stephanie J et al. (2017) Environmental Enrichment Induces Pericyte and IgA-Dependent Wound Repair and Lifespan Extension in a Colon Tumor Model. Cell Rep 19:760-773
Jewel Samadder, N; Valentine, John F; Guthery, Stephen et al. (2017) Colorectal Cancer in Inflammatory Bowel Diseases: A Population-Based Study in Utah. Dig Dis Sci 62:2126-2132
Gan, Meng; Boothe, Dustin; Neklason, Deborah W et al. (2017) Outcomes and complications of radiation therapy in patients with familial adenomatous polyposis. J Gastrointest Oncol 8:643-649
Samadder, N Jewel; Neklason, Deborah W; Boucher, Kenneth M et al. (2016) Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial. JAMA 315:1266-75
Li, Jun; Woods, Susan L; Healey, Sue et al. (2016) Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant. Am J Hum Genet 98:830-842
Kanth, Priyanka; Bronner, Mary P; Boucher, Kenneth M et al. (2016) Gene Signature in Sessile Serrated Polyps Identifies Colon Cancer Subtype. Cancer Prev Res (Phila) 9:456-65
Samadder, N Jewel; Smith, Ken Robert; Hanson, Heidi et al. (2016) Familial Risk in Patients With Carcinoma of Unknown Primary. JAMA Oncol 2:340-6

Showing the most recent 10 out of 108 publications